Fierce Biotech April 28, 2023
After collecting a long-awaited FDA clearance for the latest generation of its wearable continuous glucose monitor last December, Dexcom has offered a peek into the momentum behind its G7 diabetes sensor.
“While we are still early in our U.S. launch of G7, we have been very encouraged by the initial response,” Dexcom CEO Kevin Sayer said on the company’s earnings call with investors this week. “Nearly 1,000 health care providers have prescribed G7 who were previously not prescribing a Dexcom CGM.”
“We’ve added more users in the first quarter than we ever have in any quarter in Dexcom’s history,” added the company’s chief financial officer, Jereme Sylvain.
For the first three...
Today's Sponsors
Today's Sponsor